Small cell lung cancer (SCLC) is a recalcitrant malignancy with elusive mechanism of
pathogenesis and dismal prognosis. Over the past decades, platinum-based chemotherapy …

Summary Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …

Phenotypic plasticity of cancer cells can lead to complex cell state dynamics during tumor
progression and acquired resistance. Highly plastic stem-like states may be inherently drug …

Intratumoral heterogeneity is a seminal feature of human tumors contributing to tumor
progression and response to treatment. Current technologies are still largely unsuitable to …

Anticipating and understanding cancers' need for specific gene activities is key for novel
therapeutic development. Here we utilized DepMap, a cancer gene dependency screen, to …

Mechanistic models of biological processes can explain observed phenomena and predict
responses to a perturbation. A mathematical model is typically constructed using expert …

The understanding of small cell lung cancer (SCLC) biology has increased dramatically in
recent years, but the processes that allow SCLC to progress rapidly remain poorly …

Simple Summary Small cell lung cancer (SCLC) is an aggressive cancer that is difficult to
treat. There are at least five subtypes of SCLC cells, defined by gene expression signatures …

Breast cancer (BC) is the most commonly diagnosed cancer among women. Prognosis has
improved over the years, to a large extent, owing to personalized therapy informed by …

The olfactory epithelium undergoes neuronal regeneration from basal stem cells and is
susceptible to olfactory neuroblastoma (ONB), a rare tumor of unclear origins. Employing …